Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supriya LifescienceNSE:SUPRIYA -2.10%80 Days Payable is 96.03 as of Mar. 2026, which is 3% below its 10-year median of 98.85. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 80/100 and a GF Value™ of ₹811.57 (Fairly Valued). The stock has 3 warning signs investors should review. Among 701 Biotechnology companies, Supriya Lifescience ranks better than 53.21% on this metric.
The historical rank and industry rank for Supriya Lifescience's Days Payable or its related term are showing as below:
NSE:SUPRIYA'
s Days Payable Range Over the Past 10 Years
Min: 79.38 Med: 98.85 Max: 133.19
Current: 125.36
During the past 8 years, Supriya Lifescience's highest Days Payable was 133.19. The lowest was 79.38. And the median was 98.85.
NSE:SUPRIYA's Days Payable is ranked better than 53.21% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs NSE:SUPRIYA: 125.36
Supriya Lifescience's Days Payable
declined
from Mar. 2025 (124.07) to Mar. 2026 (96.03).
It may suggest that Supriya Lifescienceaccelerated paying its suppliers.
Supriya Lifescience Days Payable Related Terms
Supriya Lifescience Days Payable Historical Data
* Premium members only.
The historical data trend for Supriya Lifescience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SUPRIYA vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Supriya Lifescience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supriya Lifescience Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Supriya Lifescience's Days Payable distribution charts can be found below:
* The bar in red indicates where Supriya Lifescience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Supriya Lifescience's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supriya Lifescience (NSE:SUPRIYA) has a Days Payable of 96.03 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Supriya Lifescience and its competitors. This is near median its historical median of 98.85. Over the past decade, Supriya Lifescience's Days Payable has ranged from 79.38 to 133.19. According to the industry distribution chart, Supriya Lifescience ranks #328 out of 701 companies in the Biotechnology industry, placing it in the top 46.8%.
Is Supriya Lifescience's Days Payable too high?
Supriya Lifescience's current Days Payable of 96.03 is near median its 10-year median of 98.85. Over the past 10 years, this metric has ranged from a low of 79.38 to a high of 133.19. The Biotechnology industry median Days Payable is 112.84. Supriya Lifescience's value of 96.03 is 14.9% below this industry median. Based on the distribution chart, Supriya Lifescience ranks #328 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Supriya Lifescience has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Supriya Lifescience ranks #328 out of 701 companies for Days Payable. This puts Supriya Lifescience in the upper half of its industry. The industry median Days Payable is 112.84. Supriya Lifescience's value of 96.03 is 14.9% below this benchmark. Historically, Supriya Lifescience's own Days Payable has ranged from 79.38 to 133.19 over the past decade. While the company's 10-year median is 98.85 vs. the industry median of 112.84, Supriya Lifescience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supriya Lifescience's current Days Payable of 96.03 is 14.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Supriya Lifescience and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supriya Lifescience's current Days Payable is 96.03, which is near median its own 10-year median of 98.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Fairly Valued. The stock's GF Value™ is ₹811.57, compared to a current price of ₹852.40 — trading 5% above its estimated fair value. The current Days Payable is 96.03, which is near median its 10-year median of 98.85 and 14.9% below the Biotechnology industry median of 112.84. Supriya Lifescience's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current Days Payable is 96.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?
Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued.
The current stock price of ₹852.40 is trading 5% above its estimated GF Value™ of ₹811.57.
GuruFocus considers Supriya Lifescience to be Fairly Valued.
Key valuation signals for NSE:SUPRIYA:
Days Payable: 96.03 (near median its 10-year median of 98.85)
GF Value™: ₹811.57 vs. price of ₹852.40 (5% above fair value)
Industry Position: 14.9% below the Biotechnology median (#328 of 701)
No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
80GF Score
Get the complete analysis for NSE:SUPRIYA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUPRIYA has been successfully added to your 
